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Abstract
We present a new mathematical model of colorectal cancer growth and its response to monoclonal-
antibody (mAb) therapy. Although promising, most mAb drugs are still in trial phases, and the
possible variations in the dosing schedules of those currently approved for use have not yet been
thoroughly explored. To investigate the effectiveness of current mAb treatment schedules, and to
test hypothetical treatment strategies, we have created a system of nonlinear ordinary differential
equations (ODE) to model colorectal cancer growth and treatment. The model includes tumor
cells, elements of the host’s immune response, and treatments. Model treatments include the
chemotherapy agent irinotecan and one of two monoclonal antibodies - cetuximab, which is FDA-
approved for colorectal cancer, and panitumumab, which is still being evaluated in clinical trials.
The model incorporates patient-specific parameters to account for individual variations in immune
system strength and in medication efficacy against the tumor. We have simulated outcomes for
groups of virtual patients on treatment protocols for which clinical trial data are available, using
a range of biologically reasonable patient-specific parameter values. Our results closely match
clinical trial results for these protocols. We also simulated experimental dosing schedules, and
have found new schedules which, in our simulations, reduce tumor size more effectively than current
treatment schedules. Additionally, we examined the system’s equilibria and sensitivity to parameter
values. In the absence of treatment, tumor evolution is most affected by the intrinsic tumor growth
rate and carrying capacity. When treatment is introduced, tumor growth is most affected by drug-
specific PK/PD parameters.
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2010 Mathematics Subject Classification: 92-02; 92C37; 92C45
1 Introduction
According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed
cancer and the third leading cause of cancer death in both women and men in the United States [4].
Monoclonal antibodies have been explored as an adjuvant treatment for colorectal cancer, but there
are still many unanswered questions about their effectiveness and optimal use. The goal of this work
is to contribute to the understanding of how best to incorporate monoclonal antibodies into colorectal
cancer treatment. We present a system of nonlinear ordinary differential equations (ODEs), that
models the growth of a colorectal tumor, its interactions with the host’s immune system, and the
effects of three treatment options: the chemotherapy drug irinotecan, and two monoclonal-antibody
(mAb) treatments, cetuximab and panitumumab. We use this model to run clinical trial simulations
over cohorts of virtual patients with varying response rates. After validating our outcomes against
published clinical trial data, we then explore alternate hypothetical treatment scenarios.
Acronyms: mAb: monoclonal antibody, ODE: ordinary differential equation, NK:Natural Killer cell,
CD8+:cytotoxic T-cell, CTL:cytotoxic T-lymphocyte (often equivalent to CD8+ T-cell), ADCC:antibody-
dependent cellular cytotoxicity, EGF:endothelial growth factor, EGFR:endothelial growth factor
receptor, CDC:complement-dependent cytotoxicity
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Colorectal Cancer
Monoclonal antibody therapies, which are targeted cancer therapies, are being tested in clinical trials
to address colorectal tumors that are chemotherapy-refractory. Monoclonal antibodies are small
antibodies that are manufactured to bind to specific proteins. Multiple protein targets can be used,
but epithelial growth factor receptor (EGFR) is a common and useful choice. EGFRs are found in
cell membranes in cells all over our body, and circulating epithelial growth factor (EGF) binds to this
receptor and signals a cascade in the cell, resulting in cell proliferation. The increased growth rate in
tumor cells is usually caused by multiple mutations, but a common mutation upregulates the number
of EGFRs [22, 44, 34, 19]. Monoclonal antibodies targeting EGFRs are considered promising since
many cancerous cells have the EGFR-upregulating mutation.
Cetuximab and panitumumab, both monoclonal antibodies that bind to EGFR and block EGF from
binding, are two monoclonal antibodies that have been shown to have some degree of effectiveness
against colorectal cancer. Cetuximab, used with or without the chemotherapy drug irinotecan, has
been shown to improve survival times and quality of life [34]. It is an IgG1 antibody, a subclass of
antibodies that is able to elicit antibody-dependent cellular cytotoxicity (ADCC) from Natural Killer
(NK) cells, thus increasing the NK cells’ cytotoxicity [34]. Panitumumab is a newer drug and has
undergone fewer clinical trials. It has been shown to decrease tumor growth rate, but the clinical trials
have not yet been able to confirm that it increases overall survival time [34]. Both cetuximab and
panitumumab are able to activate the cascade known as complement dependent cytotoxicity (CDC),
and both increase chemotherapy’s toxicity to tumor cells by hindering their ability to reproduce [19].
There are three main pathways for mAb induced tumor death (see Figure 1): interactions between
mAbs, NK cells, and tumor cells; interactions between mAbs, chemotherapy and tumor cells; and
interactions only between mAbs and tumor cells, resulting in growth rate reduction, complement
activation, and possibly other mechanisms for tumor death.
Currently, monoclonal-antibody treatments are mainly used in patients with metastatic cancer,
particularly when no other treatment has worked [34]. However, it is possible that with positive
results from current clinical trials, monoclonal antibodies may become a more significant part of
colorectal-cancer treatment. The model presented here can shed further light on monoclonal antibody
treatments by simulating clinical trials.
Previous Models
A variety of approaches has been taken to the mathematical modeling of colorectal cancer growth and
treatment. These include ODE models, spatial models, and statistical models. A nice review can be
found in [6], where mechanistic models and phenomenological cell population models are discussed.
The primary focus of this review is to explore published models that include chemotherapy, with the
end goal of optimizing therapy regimens. In particular, in [5] a PK-PD model of irinotecan (CPT11)
is combined with a compartment model to describe a whole-body physiologically based model for
colon cancer in mice. In the model presented in this paper, we include immunotherapy in addition to
chemotherapy, using a phenomenological cell population model.
In [26], Johnston et al. considered two different approaches to the modeling of cells in a colonic
crypt. They first consider an age-structured model which tracks the locations, properties, and ages
of stem cells, transit cells, which move up the wall of the crypt to the surface, and differentiated
cells. The resulting model was then simplified using a continuous approximation. They found that
the resulting ODE system provided a good approximation for the growth rate produced by the age-
structured model for a sufficiently large time scale. This work which shows that an ODE system
can be used to represent a 3D structure in the colon, motivated our choice of model for a colorectal
tumor. However, the use of ODEs requires the simplifying assumption that the tumor is spatially
homogeneous, and only tracks tumor population changes over time. Since the measure of overall
tumor size is used to indicate the strength of a patient’s response to treatment in the clinic, it is
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Figure 1: Three methods of mAb-induced tumor cell death are represented
in this model. If an NK cell is present then the cell can undergo ADCC, if
a chemotherapy molecule is present then the cell will increase death from the
chemotherapy drug, and otherwise, the mAb molecule will cause tumor cell death
on its own, through a variety of mechanisms.
reasonable use tumor size as a measure of treatment efficacy in our model as well.
Other mathematical models of colonic cancer focus on the initiation of the disease. For example,
in [27] a mathematical model is developed that supports the hypothesis that two types of genetic
instability can lead to the tumorigenesis in individuals with colorectal cancer. More recently, Lo et al
([33]) propose a mathematical model of the initiation of colorectal cancer that explores a possible link
with colitis.
The model presented here is an extension of the work of de Pillis et al. [15], in which a tumor-
cell population, immune-cell populations, and drug concentrations are modeled with a system of
nonlinear ODEs. The model by de Pillis et al. also includes patient-specific parameters representing
the strength of the patient’s immune system, and has been validated with published studies on
mice and humans [17]. It has successfully demonstrated the need for immunotherapy in addition
to chemotherapy to prevent the tumor from growing again after drug therapies have been completed,
and was used to study the importance of the patient-specific parameters in the effectiveness of
immunotherapy treatment [15, 16]. The new model includes terms for monoclonal-antibody treatment
and its effects on the cell populations, and parameter values have been adjusted to reflect dynamics
specific to colorectal cancer.
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2 Mathematical Model
The goal of this mathematical model is to describe tumor growth, immune response, and treatments,
including chemotherapy and monoclonal antibody (mAb) treatments. Our model tracks the following
populations and quantities:
• Cell Populations
T (t) the total tumor cell population;
N(t) the concentration of NK cells per liter of blood (cells/L);
L(t) the concentration of cytotoxic T lymphocytes (CD8+) per liter of blood (cells/L);
C(t) the concentration of lymphocytes per liter of blood, not including NK cells and active
CD8+T cells (cells/L).
• Medications and Cytokines
M(t) the concentration of chemotherapy per liter of blood (mg/L);
I(t) the concentration of interleukin per liter of blood (IU/liter);
A(t) the concentration of monoclonal antibodies per liter of blood (mg/liter);
The specific treatments that we will explore are the chemotherapeutic drug irinotecan (CPT11),
and mAbs Cetuximab or Panatumumab.
• Treatments:
vM (t) the amount of irinotecan injected per day per liter of blood (mg/liter per day);
vA(t) the amount of monoclonal antibodies injected per day per liter of blood (mg/liter per
day).
In the following section, we give a description of the equations describing the evolution of each
of population. In Section 3 examples of the evolution of simulated cell populations over time are
presented, and treatments and clinical trials were simulated. Finally, we present a parameter sensitivity
analysis and discuss the results. Details of the parameter estimation, a discussion of equilibria and
their stability and further sensitivity analyses are given in the Supplementary Materials.
Equations
The full system of ODEs of the model is given below. The equations are based on the model proposed
in [15], with additions necessary to describe mAb and combination treatments. These additional
terms are shown in bold face. A summary of the purpose of each model term can be found in
Tables 1-6.
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dT
dt
= aT (1− bT )− (c+ ξ A
h1 +A
)NT −DT
− (KT +KATA)(1− e−δTM )T −ψAT (2.1)
dN
dt
= eC − fN − (p+ pA A
h1 +A
)NT +
pNNI
gN + I
−KN (1− e−δNM )N (2.2)
dL
dt
=
θmL
θ + I
+ j
T
k + T
L− qLT + (r1N + r2C)T − uL
2CI
κ+ I
−KL(1− e−δLM )L+ pILI
gI + I
(2.3)
dC
dt
= α− βC −KC(1− e−δCM )C (2.4)
dM
dt
= − γM + vM (t) (2.5)
dI
dt
= − µII + φC + ωLI
ζ + I
(2.6)
dA
dt
= − ηA−λT A
h2 +A
+ vA(t) (2.7)
where
D = d
(L/T )l
s+ (L/T )l
. (2.8)
Model Terms Describing Growth and Interactions
Each of Equations (2.1) - (2.7) describes the time evolution of one of the eight system variables. Each
equation contains a growth, or source, term, and a decay term. Most of the equations also contain
interaction terms that describe how one population of cells or molecules affects another. For example,
in Equation (2.1), the tumor is assumed to grow logistically in the absence of other cells or antibodies.
The competition term between tumor and NK cells follows a mass action law, where the effectiveness
of the NK cells in killing tumor cells, or the per cell kill rate, is enhanced by the presence of monoclonal
antibodies (see also the discussion below). The interaction between cytotoxic T lymphocytes (CTLs)
and tumor cells is described by a ratio-dependent law, articulated in Equation (2.8). The derivation of
this term is described in detail in [17].
A recruitment term is included for the tumor-specific CD8+ T cells, as well as a production term
in Equation (2.6) that reflects the increased presence of IL-2 when CTLs are present. Interleukin,
whose concentration is denoted by the variable I(t), activates the production of NK cells and CD8+
cells, indicated by the positive saturating terms in Equations (2.2) and (2.3). However, IL-2 can also
also aid in the inactivation of CD8+ cells. From Abbas et al. [1], we find that the deactivation of
CD8+T cells occurs through a pathway that requires IL-2 and the action of CD4+T cells (found in the
circulating lymphocytes). Moreover, it occurs only at high concentrations of activated CD8+T cells.
This deactivation is represented by the term −uL2CI
κ+I
in Equation (2.3).
Also described in the model are the effects of a cytotoxic drug such as irinotecan. This drug
is assumed to have a detrimental effect on all of the cell populations. For more details on the
derivation of these terms see [15] and [14], and for parameter values, sources, and derivations see
the Supplementary Materials.
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Discussion of Terms Describing Treatment
In this section we give details on terms in the model that were added to the one proposed in [15].
In Equation (2.1), three terms represent the three pathways of mAb-induced tumor-cell death (see
Figure 1).
• The term−ξ A
h1+A
NT represents the rate of tumor-cell death caused by ADCC. Some monoclonal
antibodies have protein structures which, when bound to a tumor cell, allow them to simultaneously
activate NK cells and to direct them to the invader [19]. Thus, when a mAb/tumor-cell complex
and NK cell meet, the tumor cell is more likely to be killed than when an NK cell meets
an unbound tumor cell. Kurai and colleagues [28] found that cetuximab has a threshold
concentration above which ADCC activity no longer increases. So, we assume that ADCC
activity increases with mAb concentration until it becomes saturated, and we model this with a
sigmoid function.
• The term −KATA(1− e−δTM )T represents the rate of chemotherapy-induced death of tumor
cells, assisted by monoclonal antibodies. When tumor cells are not able to proliferate, they are
much more susceptible to chemotherapy-induced death [19]. So, when mAbs are bound to
tumor cells, blocking their EGFRs and thus inhibiting tumor cell proliferation, they increase the
tumor-cell death caused by chemotherapy.
• The term−ψAT accounts for the rate of tumor-cell death caused directly by tumor cell interactions
with mAbs. This term includes tumor-cell death from CDC, from a reduction in EGF binding
and thus tumor-growth rate, [19].
The term −pA Ah1+ANT in Equation (2.2) represents the rate of NK-cell death due to ADCC
interactions with tumor cells and monoclonal antibodies. We assume that ADCC activity increases
with mAb concentration until it becomes saturated. As with the term −pNT , it is assumed that NK
cells experience exhaustion of tumor-killing resources after multiple interactions with tumor cells [7].
We note that we chose not to incorporate mAb interactions in Equations (2.3), (2.4) and (2.5), since
the literature suggests that effects of mAbs are specific to tumor cells [41, 34, 22, 44, 19].
The evolution of the monoclonal antibody population is described in Equation (2.7). The term
vA(t) represents mAb treatments. Because mAbs are not produced naturally in the body, no additional
growth terms are included. The term −ηA represents the natural degradation of the mAb protein in
the body. The term −λT A
h2+A
represents the loss of available mAbs as they bind to tumor cells.
mAbs have a very strong binding affinity for their target growth-factor receptors, and there are many
growth factor receptors on every cell, so we assume that many mAbs are lost with each tumor cell.
Also, we assume that the growth factor receptors are fully saturated when the mAb concentration is
significantly higher than the growth factor receptor concentration. That is, we can approximate the
number of mAbs lost with each tumor cell as the number of growth-factor receptors on that cell, as
long as mAb concentration is not close to zero.
3 Results
Clinical Trial Simulations for Common Treatment Regimens
We used the model to explore expected responses to treatment at a population level. In particular,
we simulated response to treatment for patients with a range of immune ‘strength’. The effectiveness
of the CD8+ T-cells is described in the model by the term D described in Equation 2.8. In order
to describe a group of patients with different immune strengths, we allow the three parameters in
Equation 2.8 to take on one of four values taken from a biologically reasonable range, [15]. These
three patient-specific parameters are d, the maximum kill-rate by effector cells; s, the steepness of the
effector-cell response to the presence of tumor; and l, a measure of the non-linearity of the response.
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Table 1 lists the specific values used. Using four different values for each of the three parameters
yields 64 virtual patient types, each with a different immune system.
To account for variation between patients in tumor response to therapy, we also varied the values
of the parameters KT , the rate of tumor-cell death from chemotherapy, and ψ, the rate of cell death
induced by mAb agents. For each simulation, the values of these parameters were randomly sampled
from a distribution given by the density function
p(x) =
1
3xmax
(1− x/xmax)−2/3, 0 ≤ x < xmax,
where xmax is the maximum value of each parameter, either Kmax or ψmax. (See Table 1.)
In these clinical trial simulations, we assume that the simulated patients have slightly compromised
immune systems after already having been through other immuno-depleting therapies. MAb therapy
is currently used mainly as a last resort, after other treatments have been attempted unsuccessfully,
so we expect the tumor population size to initially be large. Initial values for the state variables reflect
this, with with a large initial tumor size, T (0) = 109 cells, and relatively low levels of NK and CD8+
lymphocytes. All initial values are given in Appendix A. Simulated treatments were administered to
each patient, represented by vM (t) and vA(t) in model equations (2.5) and (2.7).
Clinical trial simulations were run over the set of 64 virtual patients multiple times. Final tumor
size and lymphocyte counts were recorded for each patient. Lymphocyte count was used as a marker
for patient health—if the lymphocyte count dropped low enough for the patient to be considered grade
4 leukopenic, the treatment was considered to be too harsh and not useful. This minimum lymphocyte
count was determined to be 1.4 × 108, based on the WHO criteria of grade 4 leukopenia being less
than 109 total white blood cells per liter, ([50], and see also the discussion of the parameter KC in the
Supplementary Materials). Final simulated tumor sizes were categorized as a “Complete Response”
(CR), “Partial Response” (PR), or “No Response” (NR). Tumors that continue to grow are categorized
as NR, and any tumor smaller than ≈ 2.2 mm in diameter is categorized as CR. This value was
chosen since it is significantly below the clinical detection level of 5 mm in diameter, [20]. In our
analysis, we assume a spherical, homogeneous tumor, so that 2.2 mm in diameter corresponds to
27 cells. Finally, those tumors that don’t continue to grow, but are larger than 2 × 107 cells, are
categorized as PR.
We compare the results of the simulated trials to those reported in [19, 31, 13, 23, 22]. See
Table 7 for a summary of these clinical trial outcomes. Note that the published clinical trial results
for cetuximab and panitumumab that we used for comparison reported results as “Response” or “No
Response” almost exclusively, so for our clinical trial simulations of the commonly used treatments,
we group PR and CR together under “Response”. This facilitates comparison between our simulation
results and the results of reported clinical trials.
Monotherapy clinical trial simulations were performed for each of the three drugs used in our
model. An irinotecan monotherapy clinical trial was simulated, using a common treatment regimen,
and results were compared with clinical data. (The treatment details can be found in the “Treatments”
section of the Supplementary Materials). Irinotecan monotherapy simulations resulted in a total
response of 18.7%, (15.6% PR, 3.1% CR), versus an overall reported response rate of 30% (see
Figure 2(A)). This is consistent with practice, since patients getting mAb treatments are often not
very responsive to chemotherapy. Cetuximab and panitumumab clinical trials were also simulated,
using the common treatment regimens found in “Treatments”, to verify that the desired response
rate was achieved. Parameter calculations for each mAb drug involved choosing a value for ψ that
resulted in accurate clinical trial results for the mAb monotherapies, but verification of these values is
important. Cetuximab monotherapy simulations matched the expected results with a total response
rate of 10%, (10% PR, 0% CR), versus an overall reported response rate of approximately 10% (see
Figure 2(B)), and panitumumab monotherapy simulations matched the expected results with a total
simulation response rate of 12.15% (10.9% PR, 1.25% CR), versus an overall reported response
rate of 10-13% (see Figure 2(C)). Combination therapies, using either irinotecan and cetuximab or
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irinotecan and panitumumab, were also simulated. These simulations used the common treatments
for each drug and gave the two treatments simultaneously.
Figure 2: Our clinical trial simulations compared to reported clinical trial
results for irinotecan monotherapy (A), cetuximab monotherapy (B), and
panitumumab monotherapy(C). Our simulation results closely match published
results for both cetuximab and panitumumab montherapies. For irinotecan
monotherapies, the reduced response seen in our simulations is intended, since
the patients receiving mAb therapy are often not as responsive as most patients to
other treatments.
We do not currently have a way to adjust severity classification for the tumor based on patient
health. A smaller tumor in a very sick patient can be just as dangerous as a larger tumor in healthier
patient. Therefore, when examining monotherapies, which do not have particularly damaging effects
on the immune system, we measured responses after one week in order to capture the less dramatic
and potentially transient effects, which could still be helpful to patients whose immune systems have
not been severely compromised by treatments. However, in the case of combination treatments, we
chose to wait longer after treatment before measuring results. The clinical trial studies summarized
in Table 7 did not report when tumor was measured after the last treatment, so we chose to measure
tumor size four weeks after the final treatment for all simulations. Although many more patients
experienced an initial drop in tumor size as a result of the combination treatments, this drop was
frequently unhelpful to the patient because of the additional loss of immune strength associated with
the harsher combination treatments.
Our simulations match reported clinical trial results fairly closely (see Figure 3). The results from
these simulations are also provided in Table 7, along with the associated clinical trials data.
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Figure 3: Our clinical trial simulations compared to reported clinical trial
results for irinotecan and cetuximab combination therapy (A) and irinotecan
and panitumumab combination therapy (B). If simulation results are measured
one week post-treatment, they do not replicate published results for combination
therapies. However, if simulation results are measured four weeks post-treatment,
our results are very similar to published results.
Impact of Patient Specific Response Parameters on Treatments
We also ran the model to simulate individual patients, using set values for the patient-specific parameters,
to examine how the tumor and immune system interact with strong or weak responses to the medications.
The results from these simulations were plotted as cell populations/concentrations versus time. In
Figure 4, we first see how the initial tumor size determines whether the tumor ultimately shrinks or
grows to carrying capacity in the absence of treatment. In our remaining simulations that include
treatment, we ensure that the initial tumor size is chosen to be sufficiently large so that it would grow
to carrying capacity in the absence of treatment.
In Figure 5, we simulate irinotecan/cetuximab combination therapy, and can see how a modification
in an individual’s CD8+T cell response to tumor, via response functionD, affects treatment outcomes.
We also simulated the tumor response to irinotecan/panitumumab combination therapy (figure not
shown) with l = 1.6 and s = 7 × 10−3, resulting in a moderate response D, and with l = 1.3 and
s = 4×10−3, resulting in a high response D. With the moderate D, the tumor will increase to carrying
capacity with the cessation of treatment, but the stronger D allows the patient’s immune response to
eradicate the tumor.
In Figure 6, we observe how individual tumor sensitivity to either chemotherapy or mAb therapy
affects tumor size. In particular, we simulate four possible combinations: a strong response to both
chemo and mAb therapy (A), a weak response to both chemo and mAb (B), a strong response to
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chemo but a weak response to mAb (C), and a strong response to mAb but a weak response to
chemo (D).
Figure 4: Patients can end up at either the no tumor equilibrium or the large
tumor equilibrium. In (A) T (0) = 1.1 × 107 cells, in (B) T (0) = 1.4 × 107 cells. A
tumor with a small initial size will quickly shrink toward zero, a tumor with a larger
initial size will quickly grow to the carrying capacity of the system. All other initial
values are the same in both simulations.
Figure 5: Effect of patient-specific immune response function D on
tumor response to irinotecan/cetuximab treatment. Tumor response to
irinotecan/cetuximab combination therapy with l = 1.6 and s = 7 × 10−3 (A),
resulting in a moderate response D, and with l = 1.3 and s = 4×10−3 (B), resulting
in a stronger response D. With the moderate D, the tumor will increase to carrying
capacity with the cessation of treatment, but the stronger D allows the patient’s
immune response to eradicate the tumor.
In order to explore which patient-specific parameters play a role in whether a patient will respond
to treatment, the effect of the variable parameters, d, l, s, KT , and ψ, was also examined. d, l, and
s were fixed at three sets of values from the set of patient-specific parameters used for clinical trial
modeling, a “weak D” (d = 1.3, l = 2, s = 4×10−2); “moderate D” (d = 1.6, l = 1.4, s = 8×10−3);and
“strong D” (d = 2.1, l = 1.1, s = 5× 10−3 ) response. The variables KT and ψ were then varied over
their range of 0 to their maximum values, using cetuximab as the mAb drug, and the model was run
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Figure 6: Tumor responses to combination therapy with irinotecan and
panitumumab. When the tumor has a strong response (high KT and ψ, 100%
strength) to both medications (A), the tumor shrinks during the course of the
treatment. When the tumor has a weak response (low KT and ψ, 10% strength)
to both medications (B), the tumor grows toward the carrying capacity. When
the tumor has either a strong response to irinotecan and a weak response to
panitumumab (C) or a weak response to irinotecan and a strong response to
panitumumab (D), the tumor will fluxuate in size, but will stay approximately the
same size overall during the treatment course.
for 28 days with each pair of values. Figure 9(A) shows that a patient with a weak inherent immune
system cannot have a complete response, even with a full-strength response by the tumor to the
chemotherapy and mAb treatments. A strong response by the tumor to either treatment will result in
a partial response for the tumor overall. Figure 9(B) shows that a patient with a moderately strong
immune system has a chance of overpowering the tumor and obtaining a complete result, with strong
tumor responses by the tumor to both the chemotherapy and mAb drugs. The patient is more likely
however to have a partial overall response, resulting from a strong response by the tumor to only one
medication, or to have no response. Figure 9(C) shows that a patient with a strong immune system
has a good chance for a complete overall response, with a strong response by the tumor to either the
mAb or chemotherapy treatments. However, the patient will still not respond to the treatment if the
tumor is only weakly affected by both of the medications.
Clinical Trial Simulations for Hypothetical Treatments
Clinical trial simulations with hypothetical treatment combination regimens were also performed.
We explored various timings and dosing levels of irinotecan in combination with cetuximab, and
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separately, irinotecan in combination with panitumumab. Many of the combination treatments we
experimented with, which used different doses, dosing frequencies, and different start times for
each medication, were not as successful at shrinking the tumor as the current standard treatments.
However, we did find some treatment regimens which appear to result in a smaller final tumor size,
one with each of the mAb medications. These results are shown in Figure 7. For comparison, we
include one set of simulation results for tested treatments that can also be found in Table 7, as well
as the results of the two separate hypothetical dosing schedules. In Figure 7, top panel, we compare
population responses to three different combination doses of irinotecan combined with panitumumab,
and in the bottom panel, we compare irinotecan combined with cetuximab.
Hypothetical Treatment 1: One hypothetical treatment improvement can be seen when using
irinotecan combined with panitumumab, required no change in dosing levels, but a change in the
timing of the dose administration. In this case, we dose first with panitumumab, and then wait
four days to begin irinotecan doses. Irinotecan is then continued every 7 days for the remainder
of the treatment, while panitumumab continues to be administered once every two weeks, as with
a standard dosing schedule. This treatment decreased the total number of patients who did not
respond to treatments from 14.4% to 8.4%, although it also decreased the number of patients who
demonstrate a complete response from 18.1% to 11.4%. Simulation results can be seen in Figure 7,
top panel. Since the medications are not being given at the same time, the patient may experience
fewer simultaneous side effects with this treatment schedule. However, the treatment also requires
the patient to make extra trips to the hospital for treatment administration.
Hypothetical Treatment 2: In Figure 7, top panel, we also show a second hypothetical treatment,
in which the doses of both irinotecan and panitumumab are increased: The irinotecan dose is
2.8 times the standard dose, and panitumumab is 1.5 times the standard dose. However, dosing
frequency is decreased to once every three weeks for both medications. This results in a slightly
higher complete response rate of 12.2%, and a partial response rate of 71.3%.
Hypothetical Treatment 3: In the third hypothetical scenario, shown in Figure 7, bottom panel, we
look at irinotecan combined with cetuximab. In this case, we modify the dose timing only, and leave
dose amounts at standard levels. We dose first with irinotecan, and follow up with a cetuximab dose
four days later. This strategy was not particularly successful. The complete response rate was only
12.2%, as opposed to the 17.2% achieved by the standard dosing schedule.
Hypothetical Treatment 4: Treatment option 4 combines a higher dose of irinotecan and a higher
dose of cetuximab, both administered less frequently than standard treatment would require. Results
are pictured in Figure 7, bottom panel. Irinotecan is administered once every three weeks, and
cetuximab is administered once every two weeks. Treatment lasts nine weeks, so the individual
receives three irinotecan doses, and four cetuximab doses. The use of these drugs at the higher
doses, at least as monotherapies, has been reported in the literature [22, 45, 31]. The higher dosed
irinotecan/cetuximab combination increases the overall response rate from 98.9% for the standard
treatment to 100%, and increases the complete response rate from 17.2% to 60.9%.
Of all four hypothetical treatments presented, the high-dose irinotecan/cetuximab combination
appears to be the most effective. In our simulations, the lymphocyte count stayed above a specified
minimum, which is one way to measure the degree of immune system damage from the chemotherapy.
With this treatment schedule, the medications are not always given in the same weeks, which has
the benefit of the tumor population being kept low with frequent medications, while side effects for
the patient may be reduced. However, this treatment schedule also requires that the patient receive
medication every week, which may be an inconvenience (versus, for example, the treatment with
irinotecan and panitumumab being given only every 3 weeks).
Sensitivity to Parameters
Parameter sensitivity analysis was performed to determine which model parameters have the greatest
effect on tumor size, both in the absence of treatment and with different treatments. We found seven
112
British Journal of Medicine and Medical Research X(X), XX–XX, 2013
parameters that significantly affected tumor size in our simulations. In order to separate short term
and long term effects, we looked at tumor size seven days after initiation of the simulation, and again
at twenty eight days after initiation. In most cases, parameters that had a significant impact on tumor
size at day seven were also significant at day twenty eight. A full description of the parameters and
their values can be found in the supplementary information, and in Tables 1-6, but we will briefly
explain here the parameters found to be most significant.
Each parameter value was individually increased and decreased by 5% while all other parameter
values were held constant. Tumor size was measured at 7 days, when the tumor is still growing
very quickly in our model, and at 28 days, when it is close to its maximum volume in our model.
First, we analyzed parameter sensitivity in simulations with no treatments given, so treatment-related
parameters did not affect simulation outcomes. Results for parameters with the most significant
impact on outcomes are shown in Figure 8(A) and (B) at days 7 and 28. Note that, while b (which
represents the inverse of the carrying capacity) is by far the most important parameter in determining
final tumor size, a (the intrinsic tumor growth rate) is important in determining how quickly the tumor
reaches its maximum volume. The parameter l, which affects the functional form of the CTL kill
rate, has the most significant effect on non-medicated initial tumor growth of all the immune system
parameters.
A sensitivity analysis with treatment-related parameters was then performed. For chemotherapy
irinotecan treatment parameters, the final tumor size was found to be very sensitive to KT and δT ,
which determine the model’s response to the chemotherapy drug, and to γ, which represents the
excretion of the chemotherapy drug (see Figure 8(C) and (D)). Tumor regrowth between treatments
was much more dependent on γ than was the decrease in tumor size following treatments. This
makes sense, because when the chemotherapy remains in the body longer, it will be more effective
at maintaining lower tumor volumes between treatments.
We next tested the monoclonal antibody therapies, cetuximab and panitumumab, separately.
Dose timings for cetuximab and panitumumab are different, so we measured parameter sensitivity
according to the different lengths of a standard course of treatment for each treatment type. For
cetuximab, we consider one course of treatment to be on days 0, 7, 14 and 21 (four treatments total,
once per week over four weeks), whereas for panitumumab, one course of treatment is on days 0, 14,
and 28 (three treatments total, once every other week for three weeks). We then measured tumor size
one week after the last dose of the treatment course. Therefore, long term sensitivity for cetuximab
treated tumors was measured at day 28, and for panitumumab at day 35. In both cases, the final
tumor size was found to be sensitive to ψ, the strength of the tumor’s response to mAb drugs, and to
η, the mAb turnover rate (see Figure 8(E-H)). This is reasonable, since the main anti-tumor activity
of mAb medications is through interference with the ability of EGF to bind to EGFR on the tumor cell
surface, an activity which is included in the term ψ [19]. In the short term, cetuximab also shows
some sensitivity to ξ and pA, which are the parameters that determine the strength of ADCC activity.
We note that a five percent change in all the remaining paramaters negligibly affected final
tumor size. In particular, the parameter KTA, which represents the increase in effectiveness of
chemotherapy when it is used in conjunction with mAb therapy, had very little effect on final tumor
size. In this case, the final tumor size after 28 days changed by less than 0.5 percent with a five
percent change in KTA (figure not shown).
4 Discussion
We have extended the mathematical model presented in [15] to include monoclonal antibody treatment.
We have tuned the parameter values of the model to make them specific to colorectal cancer,
the chemotherapy treatment irinotecan, and the monoclonal antibody treatments cetuximab and
panitumumab. Two stable equilibrium states were found numerically, a no tumor equilibrium and
a large tumor equilibrium. Tumors can be driven to either of these states in simulations, depending
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on the relative strength of the patient’s immune system and the treatments given.
Colorectal tumors can have a wide variety of mutations, and some of these mutations limit a
medication’s ability to function fully. The parameters KT and ψ represent a range of different tumor
responses to the same chemotherapy and mAb treatments. At the beginning of a simulation for an
individual, values for these parameters can be chosen randomly from within proscribed biological
ranges. Use of these randomly chosen variables allows us to replicate the population level results
seen in clinical trials.
A clinical study can be simulated by numerically solving the model multiple times to represent
each individual outcome in the study. In our simulations, we solved the model with 64 different
combinations of patient parameters. When simulating individuals receiving mAb monotherapy, the
resulting population level response rates are quantitatively very close to the reported rates from
clinical trials.
The simulation response rates for irinotecan chemotherapy was lower than the response rates
reported in [19]. We intentionally chose model parameters to yield this outcome. This is because
we are assuming that our cohort of 64 individuals have already have had chemotherapy with less
success than would be seen in a general population, and are therefore in need of additional mAb
therapy [13]. On the other hand, the cohort in [19] was from the general population.
For combination therapies, our tumor population responded too well to the medication short
term, although in the long term, our simulated responses matched experimental response rates well.
The short-term over-responsiveness could be caused by inaccuracies in the model parameters or
by time frame differences in the reported response rates. One possible inaccuracy in the model
is that the variability in tumor responses to medication may not be accurately represented by the
random variables. Tumors cells that aren’t destroyed by one medication may be less likely to respond
to another medication as well, such as cells in the center of the tumor, to which the medications
would have limited access. Because mAbs and chemotherapy drugs generally have very different
targets and mechanisms, a mutation causing the tumor to be refractory to one medication won’t
necessarily cause it to be refractory to the other, but it is possible. If that were the case, one
model improvement might be to use one random variable to represent the tumor’s response to both
medications, instead of two variables. Most response rates are not actually reported with a time
frame, so the response rates found with this model from four weeks post-treatment may be more
consistent with real life measurements than the response rates from one week post-treatment. If
this is the case, our model closely matches response rates for combination therapies as well, and
the apparent over-responsiveness seen in our model with combination therapies is just caused by
taking tumor measurements too early. Reported clinical trials for the dual treatments also often did
not specify irinotecan dosing, whether the patients previously received treatment, or how long the
treatment was given, so this may be responsible for part of the difference in response rates as well.
Overall, our model gives a qualitatively good prediction of likely results for various dosing schedules.
In many of the experimental treatments, particularly in the high-dose treatments, the simulated
individuals’s immune system was also greatly weakened by the treatments, particularly by irinotecan.
Thus, although the tumor cell population was greatly reduced by the treatments, the individual’s
immune system was still unable to destroy the remaining tumor cells. Although we did not find much
information about the use of CD8+T-cell treatments for colorectal cancer in the literature, the addition
of this treatment during the chemotherapy and mAb drug courses could help to bolster the immune
system and allow the patient’s immune response to lyse tumor cells more effectively. This model, with
the addition of a CD8+T cell treatment component, could be used to test this treatment hypothesis.
The parameter sensitivity analysis yielded results that were intuitively reasonable. The analysis
also serves to highlight which parameters could be possible targets for reducing tumor size. For
example, if we can get a better sense of biologically how to influence l, a parameter that affects the
functional form of the CTL kill rate, a large decrease in l would result in an immune system that is
able to conquer the tumor much more easily than the immune system resulting from a change in the
other immune system parameters.
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In the future, two modifications to this model could yield even more realistic outcomes. First, we
could tailor the parameters KT and ψ to have a more specific biological meaning. For example, the
KRAS mutation is known to be present in about 40% of all colorectal tumors, and is known to reduce
the effectiveness of mAb treatment to almost zero [18, 2]. Information such as the EGFR counts on
the tumor cells and the presence or absence of the KRAS mutation in an individual’s tumor could
allow for more personalized and specific parameter values, chosen from a smaller distribution based
on features of the tumors cells, instead of from a larger random distribution. Second, an equation
representing patient well-being could be very useful for predicting effective treatments. Although using
lymphocyte count allows us to determine that the patient’s immune system has not been completely
destroyed by the medication, it doesn’t take into account factors such as the inconvenience of frequent
treatments, the fact that high doses of cytotoxic medication may result in side effects harmful to cells
of the body other than immune cells (such as those of the stomach lining).
There are several notable clinical observations that are important in informing the next stages of
model development. One of these is that tumor cells become resistant to chemotherapeutic drugs,
making disease progression very sensitive to the timing and dosing used in treatments, [6]. The
expansion of the model to include a tumor population resistant to a particular drug would allow in
silico testing of a variety of treatment scenarios. Another aspect of treatment to bear in mind is
the effect of an individual’s circadian fluctuations on the tumor’s susceptibility to cytotoxic agents.
These periodic fluctuations can be captured in our model by allowing time-varying parameters or by
introducing delays into the model. Some models of colon cancer that do include circadian rhythms
are discussed in [6] and in the references therein.
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Figure 7: Response rates from clinical trial simulations, comparing standard
treatment to two experimental treatment schedules. Top panel is irinotecan and
panitumumab. Bottom panel is irinotecan and cetuximab. NR, No Response. PR,
Partial Response. CR, Complete Response. 320 individuals simulated. Dosing
details in Table 8.
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Figure 8: Sensitivity of final tumor size to a 5% change in parameters. Final
tumor size was measured at 7 days to capture short-term sensitivity and at 28
days (no medication, irinotecan parameters, and cetuximab parameters) or 35 days
(panitumumab parameters) to capture sensitivity after treatments are completed.
With no medication, final tumor size is most sensitive to exponential growth rate (a)
and carrying capacity (b), at 7 days (A) and carrying capacity (b) at 28 days (B).
Of the parameters for irinotecan treatments, final tumor size is most sensitive to
irinotecan-induced tumor cell death rate (KT ), efficacy (deltaT ), and the elimination
rate (γ) at both 7 days (C) and 28 days (D). Of the parameters for cetuximab
treatments, final tumor size is most sensitive to the rate of cetuximab-induced
tumor death (ψ) and the elimination rate (η) at both 7 days (E) and 28 days (F).
Of the parameters for panitumumab treatments, final tumor size is most sensitive
to the rate panitumumab-induced tumor death (ψ) at 7 days (G) and both the rate
panitumumab-induced tumor death (ψ) and the elimination rate (η) at 35 days (H).
Parameters resulting in <0.05% change in final tumor size with a 5% change are
not shown.
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Figure 9: Sensitivity to the strength of ψ (∈ 0 − 2.28 L mg−1Day−1, examined
for cetuximab only) and KT (∈ 0 − 0.81 Day−1), for a patient with a weak
(A), moderate (B), and strong (C) immune response . Blue means complete
response to medication, green means partial response to medication, magenta
means no response to medication. In a patient with a weakened immune system,
the medications will not be able to completely remove the tumor, even when the
tumor cells have a maximal response to both medications. However, a patient with
a strong immune system has a good chance of eliminating the tumor, as long as
the patient’s tumor cells have some response to the medications. Parameter values
used for the immune kill rate, D are as follows. Weak response: d = 1.3, l = 2,
s = 4× 10−2; moderate response: d = 1.6, l = 1.4, s = 8× 10−3; strong response:
d = 2.1, l = 1.1, s = 5× 10−3 .
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5 Tables
Table 1: Tumor Equation Terms and Parameters.
Term Param Description and Value (Units) Source
aT (1− bT ) Logistic tumor growth
a Growth rate of tumor
2.31× 10−1 (Day−1) [12]
b Inverse of carrying capacity
2.146× 10−10 (Cells−1) [30]
−cNT NK-induced tumor death
c Rate of NK-induced tumor death
5.156× 10−14 (L Cells−1Day−1) [15]
−ξ A
h1+A
NT mAb-induced tumor death from NK cell interactions
ξ Rate of NK-induced tumor death through ADCC
6.5× 10−10 (L Cells−1Day−1)a [28]
0 (L Cells−1Day−1)b [23]
h1 Concentration of mAbs for half-maximal increase in
ADCC
1.25× 10−6 (mg L−1)a [28]
0 (mg L−1)b [23]
−DT CD8+T cell-induced tumor death
d Immune-system strength coefficient
{1.3, 1.6, 1.9, 2.1}, (Day−1) [15]
l Immune-system strength scaling coefficient
{1.1, 1.4, 1.7, 2.0}, (–) [15]
s Value of (L
T
)l necessary for half-maximal CD8+T-cell
effectiveness against tumor
{4× 10−3, 7× 10−3, 9× 10−3, 3× 10−2}, (L−1) [15]
−KT (1− e−δTM )T Chemotherapy-induced tumor death
KT Rate of chemotherapy-induced tumor death
0− 8.1× 10−1 (Day−1) [49]
δT Medicine efficacy coefficient
2× 10−1 (L mg−1) [49]
−KATA(1− e−δTM )T mAb-induced tumor death from increase in
chemotherapy effectiveness
KAT Additional chemotherapy-induced tumor death due to
mAbs
4× 10−4 (L mg−1Day−1)a ad hoc value
4× 10−4 (L mg−1Day−1)b ad hoc value
−ψAT mAb-induced tumor death
ψ Rate of mAb-induced tumor death
0− 2.28× 10−2 (L mg−1Day−1)a [19]
0− 3.125× 10−2 (L mg−1Day−1)b [19]
Descriptions of the biological relevance of each term and parameter and the parameter values in
T (t), which tracks the tumor cell population.
a For cetuximab.
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b For panitumumab.
Table 2: NK Cell Equation Terms and Parameters.
Term Param Description and Value (Units) Source
eC Production of NK cells from circulating
lymphocytes
e
f
Ratio of NK cell synthesis rate with turnover
rate
1
9
(–) [15]
−fN NK turnover
f Rate of NK cell turnover
1× 10−2 (Day−1) Modified from [15]
−pNT NK death by exhaustion of tumor-killing
resources
p Rate of NK cell death due to tumor interaction
5.156× 10−14 (L Cells−1Day−1) [15]
−pA Ah1+ANT Additional NK death by exhaustion of tumor-
killing resources from mAb interactions
pA Rate of NK cell death due to tumor-mAb
complex interaction
6.5× 10−10 (L Cells−1Day−1)a [28]
0 (L Cells−1Day−1)b [23]
pNNI
gN+I
Stimulatory effect of IL-2 on NK cells
pN Rate of IL-2 induced NK cell proliferation
5.13× 10−2 (Day−1) [15]
gN Concentration of IL-2 for half-maximal NK cell
proliferation
2.5036× 105 (IU L−1) [15]
−KN (1− e−δNM )N Death of NK cells due to chemotherapy
toxicity
KN Rate of NK depletion from chemotherapy
toxicity
9.048× 10−1 (Day−1) [10]
δN Chemotherapy toxicity coefficient
2× 10−1 (L mg−1) [49]
Descriptions of the biological relevance of each term and parameter and the parameter values in
N(t), which tracks the concentration of NK cells.
a For cetuximab.
b For panitumumab.
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Table 3: CD8+ T Cell Equation Terms and Parameters.
Term Param Description and Value (Units) Source
θmL
θ+I
CD8+T-cell turnover
θ Concentration of IL-2 to halve CD8+T-cell
turnover
2.5036× 10−3 (IU L−1) [15]
m Rate of activated CD8+T-cell turnover
5× 10−3 (Day−1) Modified from [15]
j T
k+T
L CD8+T-cell stimulation by CD8+T cell-lysed
tumor-cell debris
j Rate of CD8+T-cell lysed tumor cell debris
activation of CD8+ T cells
1.245× 10−4 (Day−1) Modified from [15]
k Tumor size for half-maximal CD8+T-lysed
debris CD8+T activation
2.019× 107 (Cells) [15]
−qLT CD8+T-cell death by exhaustion of tumor-
killing resources
q Rate of CD8+T-cell death due to tumor
interaction
5.156× 10−17 (Cells−1Day−1) Modified from [15]
r1NT CD8+T-cell stimulation by NK-lysed tumor-cell
debris
r1 Rate of NK-lysed tumor cell debris activation
of CD8+T cells
5.156× 10−12 (Cells−1Day−1) [15]
r2CT Activation of natvie CD8+T cells in the general
lymphocyte population
r2 Rate of CD8+T-cell production from
circulating lymphocytes
1× 10−15 (Cells−1Day−1) Modified from [15]
−uL2CI
κ+I
Breakdown of surplus CD8+T cells in the
presence of IL-2
u CD8+T-cell self-limitation feedback coefficient
3.1718× 10−14 (L2Cells−2Day−1) [15]
κ Concentration of IL-2 to halve magnitude of
CD8+T-cell self-regulation
2.5036× 103 (IU L−1) [15]
−KL(1− e−δLM )L Death of CD8+T cells due to chemotherapy
toxicity
KL Rate of CD8+T-cell depletion from
chemotoxicity
4.524× 10−1 (Day−1) [10]
δL Chemotherapy toxicity coefficient
2× 10−1 (L mg−1) [49]
pILI
gI+I
Stimulatory effect of IL-2 on CD8+T cells
pI Rate of IL-2 induced CD8+T-cell activation
2.4036 (Day−1) [15]
Table cont’d on next page.
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Table 3 – continued from previous page
Term Param Description and Value (Units) Source
gI Concentration of IL-2 for half-maximal
CD8+T-cell activation
2.5036× 103 (IU L−1) [15]
Descriptions of the biological relevance of each term and parameter and the parameter values in
L(t), which tracks the concentration of CD8+ T cells.
Table 4: Lymphocyte Equation Terms and Parameters.
Term Parameter Description and Value (Units) Source
α Lymphocyte synthesis in bone marrow
α
β
Ratio of rate of circulating lymphocyte production to
turnover rate
3× 109 (Cells L−1) [24]
−βC Lymphocyte turnover
β Rate of lymphocyte turnover
6.3× 10−3 (Day−1) [15]
−KC(1− e−δCM )C Death of lymphocytes due to chemotherapy toxicity
KC Rate of lymphocyte depletion from chemotherapy
toxicity
5.7× 10−1 (Day−1) [10]
δC Chemotherapy toxicity coefficient
2× 10−1 (L mg−1) [49]
Descriptions of the biological relevance of each term and parameter and the parameter values in
C(t), which tracks the concentration of other lymphocytes.
Table 5: Interleukin-2 Equation Terms and Parameters.
Term Parameter Description and Value (Units) Source
−µII IL-2 turnover
µI Rate of excretion and elimination of IL-2
11.7427 (Day−1) [15]
φC Production of IL-2 due to naive CD8+T cells and
CD4+T cells
φ Rate of IL-2 production from CD4+/naive CD8+T cells
1.788× 10−7 (IU Cells−1Day−1) [15]
ωLI
ζ+I
Production of IL-2 from activated CD8+T cells
ω Rate of IL-2 production from CD8+T cells
7.88× 10−2 (IU Cells−1Day−1) [15]
ζ Concentration of IL-2 for half-maximal CD8+T-cell IL-2
production
Table cont’d on next page.
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Table 5 – continued from previous page
Term Parameter Description and Value (Units) Source
2.5036× 103 (IU L−1) [15]
Descriptions of the biological relevance of each term and parameter and the parameter values in
I(t), which tracks the concentration of interleukin-2.
Table 6: Medication Equations Terms and Parameters.
Term Parameter Description and Value (Units) Source
Chemotherapy
−γM Excretion and elimination of chemotherapy
γ Rate of excretion and elimination of chemotherapy drug
4.077× 10−1 (Day−1) [10]
mAb Therapy
−ηA Excretion and elimination of mAbs
η Rate of mAb turnover and excretion
1.386× 10−1 (Day−1)a [23]
9.242× 10−2 (Day−1)b [23]
−λT A
h2+A
Loss of mAbs due to tumor-mAb binding
λ Rate of mAb-tumor cell complex formation
8.9× 10−14 (mg Cells−1L−1Day−1)a [21]
8.6× 10−14 (mg Cells−1L−1Day−1)b [21]
h2 Concentration of mAbs for half-maximal EGFR binding
4.45× 10−5 (mg L−1)a [21]
4.3× 10−5 (mg L−1)b [21]
Descriptions of the biological relevance of each term and parameter and the parameter values in
M(t) and A(t), which track the concentration of chemotherapy and mAb therapy, respectively.
a For cetuximab.
b For panitumumab.
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A Equilibria and Stability
The system, without treatment, and for the parameter ranges we use, has at least two locally stable equilibrium
points. These points were found numerically. Justification for the population sizes and concentrations used can
be found in Appendix B. One equilibrium corresponding to the absence of a tumor is E0 :
T = 0, N = 3.333× 108, L = 2.526× 104, C = 3× 109, M = 0,
I = 48.9273, A = 0,
and a large tumor equilibrium is given by EL :
T = 4.65928× 109, N = 3.333× 108, L = 5.268× 105, C = 3× 109,
M = 0, I = 1173, A = 0.
A linearization of the system (2.1) - (2.8) about these equilibrium points shows that the eigenvalues of
the Jacobian of the linear system both at E0 and EL are strictly negative. Thus, both E0 and EL are locally
asymptotically stable fixed points. This is illustrated by the numerical simulations shown in Figure 4.
For the no tumor equilibrium, E0, the eigenvalues were found to be:
{−10.98, −1.67, −0.41, −0.14, −0.046, −0.010, −0.0063},
and for the large tumor equilibrium, EL, the eigenvalues were found to be:
{−25.85, −9.81, −9.43, −0.41, −0.23, −0.0098, −0.0063}.
*Corresponding author: E-mail: depillis@hmc.edu
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B Parameters
In order to determine parameter values, we searched peer-reviewed literature for in vitro and in vivo studies of
colorectal tumor growth that could provide data for the following cases: no treatment, chemotherapy treatment
with irinotecan, mAb treatment with cetuximab, and mAb treatment with panitumumab. Some of the parameters
used here are those found by de Pillis and colleagues [15] and their derivation is not repeated. The description
and values for each parameter can also be found in Tables 1-6.
Initial Conditions
We determine initial conditions for both a healthy individual and for a colorectal cancer patient who has previously
undergone treatment for the tumor. The initial values of N , L, C, and I can be determined for each individual by
considering biological arguments for reasonable cell concentrations of patients with a “strong” and “weak” immune
system.
The no tumor equilibrium was found by considering a healthy individual with no tumor (T = 0) and receiving
no cancer treatments (M = A = 0). Because we are assuming that healthy individuals are in homeostasis, we can
set each time derivative equal to zero. N and C were found by assuming a lymphocyte count of 3.333× 109 cells
per liter of blood, which is within the range for a normal lymphocyte count, and assuming natural killer and CD8+ T
cell counts to be 10 percent and < 1 percent, respectively [1]. This gives us that C = 3.333×109×0.9 = 3×109
and N = 3.333× 109 × 0.1 = 3.333× 108. The values for L and I are taken from [15], in which L is derived from
[39] and [47], and I is taken from [38] and information provided by [37]. These calculations give us the following
values for our no tumor equilibrium:
T = 0, N = 3.333× 108, L = 2.526× 104, C = 3× 109, M = 0,
I = 48.9273, A = 0.
As discussed section A, these initial conditions correspond to a stable equilibrium state of the system. As
shown in Figure 4, left panel, values starting close to these will be drawn toward this zero tumor equilibrium.
The large tumor equilibrium was found by considering a healthy individual who has a large tumor but is
not receiving any treatment (M = A = 0). We again set the time derivatives to zero under the assumption
of homeostasis. Under conditions of an untreated tumor, we leave N and C at the same values, but use larger
values for I and L, since the presence of a tumor increases the production of cytokines [15]. We take the values of
I = 1173 and L = 5.268×105 from [15], in which L is taken from [29] and Janeway’s book on Immunobiology [25].
The value of I is from [38] and information provided by [37]. With these initial values and the parameters that can
be directly calculated from available literature, we solve for the size of a large tumor in equilibrium while solving for
the parameter p in the section on NK cell parameters. Note that the resulting value, T = 4.65928× 109, is slightly
less than the theoretical carrying capacity of 4.66 × 109 which we find during the calculation of the parameter
b in the section on tumor parameters. This is expected, because interactions with the immune system prevent
the tumor from reaching its theoretical carrying capacity. These initial values give us the following large tumor
equilibrium:
T = 4.65928× 109, N = 3.333× 108, L = 5.268× 105, C = 3× 109,
M = 0, I = 1173, A = 0.
These initial conditions also correspond to a stable equilibrium state of the system, as discussed in Appendix A. As
illustrated in Figure 4, right panel, values starting close to these will be drawn toward this high tumor equilibrium.
Since the majority of the individuals we are considering have previously undergone various treatments and
do not have very strong immune systems, we reduce the initial values for N, L, and C in our simulations. A
normal leukocyte count is 4.5−11×109 cells/L, and lymphocytes can make up 16-46% of the total leukocytes [1].
Thus a normal lymphocyte count is 0.72 − 5.06 × 109 cells/L. We set the initial total lymphocyte count in our
simulated individuals to 9.9 × 108 cells/L, a value within the normal range for lymphocyte concentration, but
close to being low. Natural killer cells and activated CD8+T cells interact more directly with the tumor than the
other lymphocytes, so we assume that they are deactivated at a slightly higher rate. Thus NK cells constitute a
slightly smaller percentage of the total lymphocytes than the normal value of 10%. We set N(0) to 9% of total
lymphocytes, so N(0) = .9 × (9.9 × 108) = 9 × 107. NK cell population was reduced to approximately 1
3
− 1
4
it’s original value, so we reduce L(0) to approximately 1
3
its original value also, and set L(0) = 1.8 × 105. This
leaves C(0) = 9 × 108. Initial values for M and A are set to zero, but dM
dt
and dA
dt
will be nonzero at any time t
when the patient is receiving treatments. Since the presence of tumor fragments stimulate IL-2 production [46],
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we leave I = 1173 as the initial value for I. The initial value of T can be varied, and is stated with simulations.
These calculations give us the following initial conditions for the “sick” populations in our model:
N(0) = 9× 107, L(0) = 1.8× 105, C(0) = 9× 108, M(0) = 0,
I(0) = 1173, A(0) = 0.
These initial values represent patients who are not in homeostasis, and depending on the initial tumor size, the
strength of interactions between the patient’s immune system and the tumor, and whether any medication is given,
their cell populations can be driven either to the no tumor equilibrium or to the large tumor equilibrium. Sample
conditions for a tumor that is reduced to the no tumor equilibrium and for a tumor that grows to the large tumor
equilibrium are found in Figure 4.
dT
dt : The tumor
For a summary of the terms, parameters, and parameter values, see Table 1.
a = 2.31 × 10−1 day−1, the tumor growth rate, was calculated from the doubling time of colorectal tumors
during exponential growth, which was found in [12] to be 3 days. We can calculate a from the equation for
exponential growth with a half-life of t = 3 days. So, 2t0 = t0eat, giving us a =
ln(2)
3
= 2.31× 10−1. This
is approximately half of the value for a found by de Pillis’s team for melanoma [15], but colon tumors are
known to have slower growth rates than most of cancers, so this is not an unreasonable value [8, 9]. It is
important to note that in [12] tumors were grown in non-immunodeficient mice, and our model considers
patients who do not have a full-strength immune response, however this was the only study in our literature
search that provided the doubling time specifically during exponential growth. The growth rate that we
calculated also agrees with the initial growth rates found in [30], who grew colon tumors in immunodeficient
mice.
b = 2.146×10−10 cells−1, is the inverse of the carrying capacity. The theoretical carrying capacity (in volume) of
colorectal tumors was taken from Leith and colleagues [30], who collected tumor growth data, fit them to
the Gompertz equation, and found the maximum tumor size as t→∞. The carrying capacity derived from
the Gompertz model has the same biological interpretation as in our model, so we were able to use the
results of [30] to find a value for b. Multiple carrying capacities were found from different colorectal tumor
lines, with an average of approximately 10,000 mm3 = 1013 µm3. This size was then converted to a cell
population using 2145 µm3 as the average tumor cell volume [11], giving 1013µm3/(2145µm3/cell)=4.66×
109 cells. Thus, b = (4.66× 109 cells)−1 = 2.146× 10−10.
c = 5.156× 10−14 L cells−1day−1, the rate of NK-induced tumor death, is set equal to p (see the section on NK
cell parameters), as was done in [15], under the assumption that when an NK cell kills a tumor cell, the
NK cell also is deactivated. Recent research [7] suggests that natural killer cells may be able to kill up to
six tumor cells before deactivation. However we have not found further confirmation of this and so have
chosen to continue using the assumption that NK cells are only able to kill one tumor cell each.
D = d
(L/T )l
s+(L/T )l
is a patient-specific term that involves three parameters to which we assign four separate values
each, in order to reflect a variety of patient-specific states. These parameters are: d (day−1), the immune-
system strength coefficient; l, the immune-system strength scaling coefficient; and s (L), the value of (L
T
)l
necessary for half-maximal CD8+ T-cell effectiveness against tumor. We base our values for d, l, and s
on the values of d ∈ {1.88, 2.34}, l ∈ {1.81, 2.09}, and s ∈ {3.5 × 10−2, 3.8 × 10−3} used in [15], and
slightly weaken the patient immune system (represented by lowering d and l and raising s) to represent
individuals who are not in good health from having gone through multiple cancer treatments. We use
d ∈ {1.3, 1.6, 1.9, 2.1}, l ∈ {1.1, 1.4, 1.7, 2.0}, and s ∈ {4× 10−3, 7× 10−3, 9× 10−3, 3× 10−2}, which
results in sixty-four different individual immune profiles over which we can run simulations to represent
clinical trials.
ξ = 6.5 × 10−10 L cells−1day−1 for cetuximab, and = 0 for panitumumab, is the rate of NK-induced tumor
death through ADCC. The value for cetuximab was set to match the expected increase in NK cell activity
found by Kurai and colleagues [28]. Kurai’s team varied concentrations of tumor cells and NK cells, left
them for 4 hours with and without 0.25µg/mL cetuximab, and measured the resulting NK activity. They
measured the activity at much higher concentrations of NK cells than are present in the body, but based
on their results we approximated that at the ratio of one NK cell to ten tumor cells, NK activity is increased
by 10 percent. We found an appropriate value for ξ by running simulations with varying values of ξ and
simulating their experimental conditions: t = 4 hours, T0 = 109, N0 = 14 × T0 = 2.5× 108, and an initial
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treatment of 0.25 mg/L cetuximab over 15 minutes. The other immune system components, as well as
natural growth and decay, were not included. A value of ξ = 6.5× 10−10 was found to give the desired 10
percent decrease in NK cells in this experiment, which we use as a proxy for an increase in NK activity of
10 percent. Panitumumab is unable to activate the ADCC pathway, so ξ is set to zero in that case [23].
h1 = 1.25 × 10−6 mg L−1 for cetuximab, and 0 for panitumumab, is the concentration of mAbs necessary for
a half-maximal increase in ADCC. The ADCC activity level indicated by ξ is reached when the cetuximab
concentration is above 0.25µg/mL, and so h1 was set to .5× 0.25µg/mL= 1.25× 10−6 mg/L. Cetuximab
levels in the body are usually above this threshold during treatment, and we have chosen to use a sigmoid
function to capture this threshold. Although we do not have evidence to support that ADCC activity
increases according to a saturation function, this model captures two important characteristics: that the
threshold concentration for maximal ADCC activity is much lower than the normal cetuximab dose, and that
the ADCC activity level approaches zero as mAb concentration approaches zero. We chose h1 so that,
when the cetuximab concentration is half of the threshold value, the term A
h1+A
equals one half, resulting
in half-maximal ADCC activity. Because panitumumab does not play a role in ADCC, panitumumab does
not have an h1 (h1 = 0).
KT = 8.1 × 10−1X day−1 is the rate of chemotherapy-induced tumor death, where X is a random variable
with probability density function p(x) = 1
3
(1 − x)−2/3, 0 ≤ x < 1. We chose this distribution since it is
supported on [0, 1], has a high probability of being close to one, and a mean of E[X] = 0.75. Therefore,
KT ∈ [0, 8.1 × 10−1], and has a mean value of KT = 6.075 × 10−1. Note that, in the clinical trial
simulations, each patient is assigned a value for KT , but a different KT is randomly generated for each
patient according to the distribution given above.
The maximal value of KT was calculated from in vitro data collected by Vilar and colleagues [49] on
irinotecan concentration and growth reduction of various colon cancer cell strains. We chose to use values
from the HT-29 cell line, in accordance with much of the literature that we reviewed. We estimated five
coordinates from data in [49], which gave irinotecan concentration (in mol/L) versus growth of tumor cells,
as a percentage of tumor cell growth with no irinotecan. Since the reported data was from an in vitro study
run over the course of only a few days, we set all but tumor size and chemotherapy concentration to zero
and assumed that the natural cell death was zero. We also assumed that chemotherapy concentration
would be held constant, so dM
dt
= 0. Thus the differential equation for the tumor population becomes
dT
dt
= −KT (1 − e−δTM )T , with solution: T = T0e−KT (1−e−δTM )t. We converted the irinotecan
concentration at each point to units of mg/L using 677 g/mol as the molecular weight of irinotecan [48].
We then used tumor sizes and chemotherapy concentrations from each data point reported in [49] to write
five equations with δT and KT as unknowns. Since the system is overdetermined (five equations, two
unknowns), we chose values for δT and KT that produced a reasonable fit. We found δT = 0.2 and
KT ≈ 0.85.
KT was then separately confirmed by running multiple simulations with our set of patient-specific parameter
values to look for a tumor response rate of approximately 15-20% after 6 weeks of treatment. The reported
response rate (the percentage of patients whose tumor was not larger after treatment) for irinotecan is
around 30 percent, however patients receiving mAb treatment have usually already received a variety of
chemotherapy treatments and did not respond strongly to them, so we aimed for a response rate lower
than this [19]. These simulations confirmed that a value of KT = 0.81 gives an average response rate of
approximately 19 percent.
KAT = 4 × 10−4 L mg−1day−1 for both cetuximab and panitumumab, is the additional chemotherapy-induced
tumor death due to mAb-tumor interactions. Even with KAT set to zero, our simulation response rates
are much higher than those reported in clinical trials, however, it is known that mAb therapy can help
to increase chemotherapy responses in tumors, and even restore partial response in chemotherapy-
refractory tumors, so we have chosen to give KAT a non-zero value of KAT = 4×10−4 [19]. At maximal
mAb concentrations, which are on the order of 102 mg, this results in an increase in chemotherapy activity
of approximately 4×10
−4×102
8.1×10−1 ≈ .05 = 5%.
δT = 2× 10−1 L mg−1, the medicine efficacy coefficient, was found as part of the calculation for KT .
ψ = 2.28 × 10−2Y L mg−1day−1 for cetuximab and 3.125 × 10−2y L mg−1day−1 for panitumumab is the
rate of mAb-induced tumor death, where Y is a random variable with probability density function p(y) =
1
3
(1−y)−2/3, 0 ≤ y < 1. Therefore, ψ ∈ [0, 2.28×10−2] for cetuximab, with a mean value of 1.71×10−2,
and ψ ∈ [0, 2.58× 10−2] for panitumumab, with a mean value of 1.94× 10−2. As with KT , multiplying the
maximum value for ψ by a random variable between zero and one allows us to represent that each tumor
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has a different response to treatments. Each patient (each simulation) has one constant value for ψ, but a
different ψ is randomly generated for every patient.
The maximum value of ψ was found by running simulations of mAb therapy over a range of possible
values for ψ, using the full set of patient-specific parameters. The values of ψ we chose yielded a 10%
response rate for cetuximab at four weeks, and a 12.2% response rate for panitumumab at six weeks.
These response rates reflect those reported in [19].
dN
dt : Natural killer cells
For a summary of the terms, parameters, and parameter values, see Table 2.
e
f
= 1
9
, the ratio of the NK cell synthesis rate to the turnover rate, is found using the same method as was
used in [15]. The value for e
f
is found by assuming the no tumor equilibrium and thus setting T = 0 and
setting Equation 2.2 to zero. We then ignore the term pNNI
gN+I
, which has only a very small effect on NK
proliferation. This gives us f( e
f
C −N) = 0, and so e
f
= N
C
. As in the equilibrium calculations, NK cells
make up approximately 10 percent of all lymphocytes, and T cell count is negligible, giving us 10%
90%
, or
1
9
[1].
f = 1×10−2 day−1, the rate of NK cell turnover, is based on the value of f = 1.25×10−2 found by de Pillis and
colleagues [15]. We lowered the value slightly to agree with our assumption of a patient with a weakened
immune system whose body may not be able to produce new cells as quickly as normal healthy individual.
gN = 2.5036× 105 IU L−1, the concentration of IL-2 needed for half-maximal NK cell proliferation, is unchanged
from the value found by in [15].
pN = 5.13 × 10−2 day−1, the rate of IL-2 induced NK cell proliferation, is calculated using the same method
as in [15]. They use data from [35] to find that 5.0073 × 104 IU stimulates NK cells to reach a count of
2.3×109 cells, and so using these as I andN respectively and assuming T = 0, we then set Equation 2.2
equal to zero and solve for pN :
pN =
f(N − e
f
C)(gN + I)
NI
.
Using C = 3 × 109 from our no tumor equilibrium and the previously calculated values for e, f , and gN ,
we find that pN = 5.13× 10−2.
p = 5.156 × 10−14 L cells−1 day−1, the rate of NK cell death due to tumor interaction, is calculated using
the same method as in [15]. We consider the large tumor equilibrium with no medication, assume (as
explained in the calculation for c) that p = c, and can thus set Equations 2.1 and 2.2 equal to zero and to
solve for T and p:
p =
pNNI
gN+I
+ eC − fN
NT
and
0 = aT (1− bT )− cNT −DT
= aT (1− bT )− pNT −DT.
We were then able to use the values for pN , gN , e, f, a, b, the equation for D with the moderate patient-
specific parameter values of d = 1.9, l = 1.6, and s = 7 × 10−3, and the state values for the immune
system populations from the large tumor equilibrium to find that T = 4.65928 × 109 in the large tumor
equilibrium and p = 5.156× 10−14.
pA = 6.5 × 10−10 L cells−1day−1 for cetuximab and 0 for panitumumab is the rate of NK cell death due to
interactions with mAb-tumor complexes. We set pA = ξ, under the approximation used for the calculation
of parameter c that for each tumor cell killed through ADCC, one NK cell also dies.
KN = 9.048 × 10−1 day−1, the rate of NK depletion from chemotherapy toxicity, is calculated using the same
method as in [15], by linearly scaling KC by the ratio of cell metabolic rates. That is,
KN =
f
β
KC .
δN = 2× 10−1 L mg−1, the chemotherapy toxicity coefficient, is assumed to equal δT . The drug has a different
efficacy (K) for each cell type, but we assume that a similar concentration of irinotecan is needed to affect
each cell, regardless of cell type [15].
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dL
dt : CD8
+T cells
For a summary of the terms, parameters, and parameter values, see Table 3.
m = 5 × 10−3 day−1, the rate of activated CD8+T-cell turnover, is based on the value of m = 9 × 10−3 found
by de Pillis and colleagues [15]. We lowered the value slightly to agree with our assumption of a patient
with a weakened immune system, whose body may not be able to produce new cells as quickly as normal
healthy individual.
θ = 2.5036 × 10−3 IU L−1, the concentration of IL-2 to halve CD8+T-cell turnover, is unchanged from de Pillis
and colleagues [15].
q = 5.156× 10−17 cells−1day−1, the rate of CD8+T-cell death due to tumor interaction, is set equal to p× 10−3
because, as de Pillis and colleagues [15] point out, we expect q to be approximately three orders of
magnitude less than p since L is approximately three orders of magnitude less than N .
r1 = 5.156× 10−12 cells−1day−1, the rate of NK-lysed tumor cell debris activation of CD8+T cells, is calculated
using the same method as in [15]. We set r1 = 100 × c, based on the approximation that a lysed tumor
cell can stimulated 10-300 T cells per day [15].
r2 = 1 × 10−15 cells−1day−1, the rate of CD8+T-cell production from circulating lymphocytes, is based on the
value of r2 = 5.8467×10−13 found by de Pillis and colleagues [15]. We reduced it from the value in [15] to
reflect that a weakened immune system may not be able to produce activated CD8+T cells as effectively.
pI = 2.4036 day−1, the rate of IL-2 induced CD8+T-cell activation, was found using the same method as
in [15]. A system of equations was created by considering the no tumor equilibrium and the large tumor
equilibrium. Setting Equation 2.3 to zero and using these two sets of initial values for T, N, L, C, and I,
we can obtain two equations each with pI and u as unknowns, and thus solve for the pI and u necessary
to make satisfy the equilibrium conditions.
gI = 2.5036 × 103 IU L−1, the concentration of IL-2 necessary for half-maximal CD8+T-cell activation, is
unchanged from the value found in [15].
u = 3.1718 × 10−14 L2 cells−2day−1, the CD8+T-cell self-limitation feedback coefficient, is obtained from the
system of equations used to calculated pI .
κ = 2.5036 × 103 IU L−1, the concentration of IL-2 to halve the magnitude of CD8+T-cell self-regulation, is
unchanged from the value found in [15].
j = 1.245 × 10−4 day−1, the rate of CD8+T-cell lysed tumor cell debris activation of CD8+T cells, is based on
the value of 1.245 × 10−2 found by de Pillis and colleagues [15], and was decreased to indicate that the
weak immune system may not be able to activate CD8 cells as effectively.
k = 2.019 × 107 cells, the tumor size for half-maximal CD8+T-cell lysed tumor debris CD8+T cell activation, is
unchanged from the value found in [15].
KL = 4.524 × 10−1 day−1, the rate of CD8+T-cell depletion from chemotherapy toxicity, is found in the same
way as we found KN . We calculated it using the same method as was used in [15], by linearly scaling
KC . That is,
KL =
m
β
KC .
δL = 2×10−1 L mg−1, the chemotherapy toxicity coefficient, is found in the same way as δN , with the assumption
that it is equal to δT [15].
dC
dt : Lymphocytes
For a summary of the terms, parameters, and parameter values, see Table 4.
α
β
= 3 × 109 cells L−1, the ratio of the rate of circulating lymphocyte production to turnover rate, is taken from
considering the steady state assumption of dC
dt
= 0 in a healthy, tumor free individual. Considering
Equation 2.4 with M = 0, we find that α
β
= C, where C = 3× 109 refers to the equilibrium value of C in
the no tumor equilibrium.
β = 6.3× 10−3 day−1, the rate of lymphocyte turnover, is unchanged from the value found in [15].
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KC = 5.7× 10−1 day−1, the rate of lymphocyte depletion from chemotherapy toxicity, was calculated to achieve
the results given by Catimel and colleagues [10] on the number of patients with leukopenia after irinotecan
treatments. Catimel’s team found that when 100 mg/m2 was given to patients daily for three days, three
out of eleven patients had leukopenia, and when 115 mg/m2 was given daily for three days, four out of
ten patients had leukopenia. A patient is considered to have leukopenia when the leukocyte count drops
below 1.9× 109 [50], and as discussed in section B, lymphocytes can comprise up to 46% of leukocytes,
so the highest possible lymphocyte count in a patient with leukopenia is 46% of 1.9 × 109, or 8.74 × 108
cells. We assume that the lymphocyte count for all patients drop equally, and so those who begin initially
with a lower lymphocyte count become leukopenic, and those who begin with a higher lymphocyte count
will have a reduced cell count, but remain within the normal range. So, the lowest three elevenths of
patients will have lymphocyte levels below 1.904 × 109 cells, and the lowest four tenths of patients will
have lymphocyte levels below 2.456× 109 cells. We ran simulations considering only lymphocyte counts,
with irinotecan delivered once daily over 1.5 hours for a total of 3 days, and found a value forKC that made
an initial lymphocyte count of 1.904 × 109 drop to approximately 8.74 × 108 with a 100 mg/m2 dose and
an initial lymphocyte count of 2.456× 109 drop to approximately 8.74× 108 with a 115 mg/m2 dose. The
two doses resulted in KC values of 0.52 and 0.63 respectively, so these were averaged to find KC = .57.
δC = 2× 10−1 L mg−1, the chemotherapy toxicity coefficient, is found in the same way as we found δL, with the
assumption that it is equal to δT [15].
dI
dt : Interleukin
For a summary of the terms, parameters, and parameter values, see Table 5.
µI = 11.7427 day−1, the rate of excretion and elimination of IL-2, is unchanged from the value found in [15].
ω = 7.88 × 10−2 IU cells−1day−1, the rate of IL-2 production from CD8+T cells, is calculated using the same
method as was used in [15], from the no tumor and large tumor equilibria. dI
dt
is set to zero, and the known
parameters and initial values are used to find two equations with the two unknowns ω and φ. We then
solve for these two parameters.
φ = 1.788×10−7 IU cells−1day−1, the rate of IL-2 production from CD4+ and naive CD8+T-cell IL-2 production,
is found as part of the system of equations solving for ω.
ζ = 2.5036 × 103 IU L−1, the concentration of IL-2 for half-maximal CD8+T-cell IL-2 production, is unchanged
from the value found in [15].
dM
dt : Irinotecan chemotherapy treatment
For a summary of the terms, parameters, and parameter values, see Table 6.
γ = 4.077 × 10−1 day−1, the rate of excretion and elimination of chemotherapy drug, is calculated using the
assumption of exponential decay from ln(2)
t1/2
, where t1/2 is the half-life of SN-38, the active form of
irinotecan, in tissue. The half-life of irinotecan in rat tissue is 7.2 hours, the half life of irinotecan in rat
plasma is 1.8 hours, the half life of irinotecan in human plasma is 8.3 hours, and the half life of SN-38
in human plasma is 10.2 hours [36, 10]. So, we assume that the ratio of the irinotecan half life in rat
tissue/rat plasma equals the ratio of irinotecan half life in human tissue/human plasma to get that the half
life of irinotecan in human tissue is 7.2×8.3/1.8 = 33.2 hours. We also assume that the ratio of irinotecan
half life in human tissue/plasma equals the SN-38 half life in human tissue/plasma, which gives us that the
half life of SN-38 in human tissue is 33.2× 10.2/8.3 = 40.8 hours. Thus γ = ln(2)
40.8/24
= 4.077× 10−1.
dA
dt : Cetuximab and panitumumab monoclonal antibody treatment
For a summary of the terms, parameters, and parameter values, see Table 6.
η = 1.386 × 10−1 day−1 for cetuximab and 9.242 × 10−2 day−1 for panitumumab is the rate of mAb turnover
and excretion. The parameter η is calculated using the assumption of exponential decay from ln(2)
t1/2
,
where t1/2 is the half-life in tissue of each mAb. For cetuximab, the half life in tissue is 5 days, so
η =
ln(2)
5
= 0.139 [23]. For panitumumab, the half life in tissue is 7.5 days, so η = ln(2)
7.5
= 0.092 [23].
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λ = 8.9×10−14 mg cells−1L−1day−1 for cetuximab and 8.6×10−14 mg cells−1L−1 day−1 for panitumumab is
the rate of mAb/tumor-cell complex formation. Average cells have around 20,000 EGFRs [3]. The binding
affinity of cetuximab is 400 pM (picomolar, which measures the ratio of the concentration of unbound
molecules to the concentration of bound molecules) and for panitumumab it is 50 pM [21]. We first consider
cetuximab, which has a molecular weight of 152 kD=152 × 106 mg/mol [42]. A binding affinity of 400 pM
means that 400 pM = [cetuximab][EGFRs]/[cetuximab-EGFR complexes]. We first need to find the number
of cetuximab-EGFR complexes per cell:
400 pmol
1L
× 1 mol
1012 pmol
= 4× 10−10 mol/L.
So, for each free cetuximab molecule and EGFR, there are 2.5×109 cetuximab-EGFR complexes. So, out
of the 20,000 EGFRs per cell, we expect < 1 (8 × 10−6) EGFR per cell to be free. Thus we will assume
that all EGFRs are filled. We can convert this back into concentration of cetuximab lost per tumor cell:
20, 000 mAbs× 1 mol
6× 1023 mAbs ×
152× 106 mg
1 mol
× 1
57L
= 8.9× 10−14 mg/L.
Thus, for cetuximab, λ = 8.9×10−14. For panitumumab, we perform a similar computation, using instead
panitumumab’s binding affinity and its molecular weight of 147 kD=147 × 106 mg/mol [43]. We first find
the number of panitumumab-EGFR complexes per cell:
50 pmol
1L
× 1 mol
1012 pmol
= 5× 10−11 mg/L.
So, for each free panitumumab molecule and EGFR, there are 2× 1010 panitumumab-EGFR complexes,
and we again assume that all EGFRs are filled. We can convert this back into mg of panitumumab lost
per tumor cell:
20, 000 mAbs× 1 mol
6× 1023 mAbs ×
147× 106 mg
1 mol
× 1
57L
= 8.6× 10−14 mg/L.
Thus for panitumumab, λ = 8.6× 10−14.
h2 = 4.45× 10−5 mg L−1 for cetuximab and 4.3× 10−5 mg L−1 for panitumumab is the concentration of mAbs
for half-maximal EGFR binding. We first consider cetuximab, and use 109 as the number of tumor cells
and 57 L as the volume of an average person [15]. Assuming that 20,000 cetuximab molecules bind to
each tumor cell, we want to find the number of mg/L at which the EGFRs are saturated:
20, 000 mAb
1 cell
× 109 tumor cells× 1 mol
6× 1023 mAb×
152× 106 mg
1 mol
× 1
57 L
= 8.9× 10−5 mg/L.
So, we set h2 = 0.5× 8.9× 10−5 = 4.45× 10−5 mg/L for cetuximab. We perform similar computation for
panitumumab:
20, 000 mAb
1 cell
× 109 tumor cells× 1 mol
6× 1023 mAb×
147× 106 mg
1 mol
× 1
57 L
= 8.6× 10−5 mg/L.
Thus we set h2 = 0.5× 8.6× 10−5 = 4.3× 10−5 mg/L for panitumumab.
Treatments
In this section we show the calculations performed to find the treatment functions (vM and vA) for the most
common treatment schedules. We also used other dosing schedules in section 3, but the methods for computing
them were the same as those we show here. Unless otherwise noted, the treatment regimens have been adapted
from De Vita’s book titled Cancer: Principles and Practice of Oncology [19].
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Irinotecan Treatments
vM (mg/L/day) has been changed to fit a common treatment regimen for irinotecan. A 125 mg/m2 dose of
irinotecan is usually given over 90 minutes once weekly, and we give it in our simulations for 4 weeks. We assume
1.73 m2 to be the average surface area of an adult [40]. Because the medication quickly leaves the blood stream,
we use 59.71 L, the average volume of an adult, as the volume over which the medication is spread [15]. So, we
would like each dose to infuse
125
mg
m2
× 1.73 m2 × (59.71 L−1) = 3.6217 mg/L,
and because it is given over 90 minutes=0.0625 days, we want to set
vM (t) =
{
57.947 mg/L/day if treatment was given at time (t− 2/24),
0 otherwise.
We check for treatments at time (t−2/24) because irinotecan needs to be converted by the body to its active
form, SN-38, and SN-38 levels reach their peak two hours after irinotecan levels [19].
Cetuximab Treatments
For cetuximab, a loading dose of 400 mg/m2 is usually given over two hours, followed by a weekly 250 mg/m2
dose over 60 minutes. Cetuximab is given on a six-week periodic schedule, during which it is given weekly for the
first four weeks, then not given for two weeks. We assume the same surface area and volume as in the previous
section. For the loading dose, we would like to infuse
400
mg
m2
× 1.73 m2 × (59.71 L−1 = 11.59 mg/L,
and because it is given over two hours=0.0833 days, we want to set
vA(t) =
11.59 mg/L
0.0833 days
= 139.072
for the first two hours of the simulations. For the regular weekly treatments, we would like to infuse
250
mg
m2
× 1.73 m2 × (59.71 L−1 = 7.243 mg/L,
and because it is given over 60 minutes=0.04167 days, we want to set
vA(t) =
7.243 mg/L
0.04167 days
= 173.840.
Thus, at any time t,
vA(t) =

139.072 mg/L/day if t ∈ (0, 2
24
)
173.840 mg/L/day if treatment was given at time t & t ≥ 2
24
0 if treatment was not given at time t.
Panitumumab Treatments
The value of vA for panitumumab was found in the same way, except that panitumumab does not require a loading
dose. We assume a treatment regimen of 6 mg/kg every two weeks, for a total of three treatments. We assume
that the medication is given over 60 minutes, and that an average adult weighs of 70 kg [32]. This gives us
vA(t) =
{
168.816 mg/L/day if treatment was given at time t
0 if treatment was not given at time t.
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Table 7: Treatment Response Rates: Simulations compared to Published
Results.
Our Results Published Results
Medicationa Dose Freq. N NR R N NR R Source
Irinotecan 125 mg/m2 q1w 320 81.3% 18.7% NP 70% 30% b [19]
Cmab 400 mg/m2 load & 320 90.0% 10.0% NP 89-91% 9-11% [19]
250 mg/m2 q1w 346 88.4% 11.6% [31]
111 89.2% 10.8% [13]
Pmab 6 mg/kg q2w 320 87.8% 12.2% NP 87% 13% [19]
231 90% 10% [22]
Irinotecan 125 mg/m2 q1w, 320 d 3.9% 96.1% NP 77.1-5% 22.5-9% [19]
and Cmab 400 mg/m2 load & 320 83.1% 16.9% NP 77% 23% [23]
250 mg/m2 q1w NP 77.1% 22.9% [13] c
Irinotecan 125 mg/m2 q1w, 320 d 14.4% 85.6% 34 80% 20% [22] c
and Pmab 6 mg/kg q2w 320 82.9% 17.1%
Response rates for common treatment schedules from clinical trials and from our simulations.
a Abbreviations: Pmab=panitumumab; Cmab=cetuximab; q1w=every week; q2w=every two weeks; q2w=every
three weeks; load=loading dose; N=number of patients; NR=no response; R=response, NP=not provided.
b Most response rates for irinotecan found in the literature are for irinotecan as a first-line treatment, including
this one. However, patients receiving mAb therapy are usually receiving it because they did not respond well to
chemotherapy [13].
c Irinotecan dosing schedule was varied during the study.
d The first response rates (RRs) are measured 7 days after completion of first treatment. The second RRs for
each are measured 4 weeks after treatments have ended.
Table 8: Simulation Response Rates: Combination Therapies with
Hypothetical Dosing Schedules
Our Resultsa
Medicationb Dose Frequencyc N NR PR CR
Irinotecand 125 mg/m2 weekly, 320 1.9% 80.9% 17.2%
and Cmab 400 mg/m2 load &
250 mg/m2 weekly
Irinotecand 125 mg/m2 weekly & 320 14.4% 67.5% 18.1%
and Pmab 6 mg/kg q2w
Irinotecan 125 mg/m2 weekly & 320 3.4% 84.4% 12.2%
and Cmab 400 mg/m2 load, day 4 &
250 mg/m2 weekly
Irinotecan 125 mg/m2 weekly, day4 & 320 8.4% 80.1% 11.4%
and Pmab 6 mg/kg q2w,
Irinotecan 350 mg/m2 q3w 320 0% 39.0% 60.9%
and Cmab 500 mg/m2 q2w
Irinotecan 350 mg/m2 q3w & 320 16.6% 71.3% 12.2%
and Pmab 9 mg/kg q3w
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Response rates from clinical trial simulations for our experimental treatment schedules.
a N=number of patients; NR=no response; PR=partial response, CR=complete response.
b Pmab=panitumumab; Cmab=cetuximab
c q3w=every three weeks; q2w=every two weeks; load=loading dose.
d The standard treatments.
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